Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

MRTX

Mirati Therapeutics Inc

Dec 01 • 04:00PM ET

57.08

Dollar change +0.33
Percentage change 0.58	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-12.22	Insider Own	8.80%	Shs Outstand	70.15M	Perf Week	0.49%
Market Cap	4.00B	Forward P/E	-	EPS next Y	-9.60	Insider Trans	69.06%	Shs Float	63.97M	Perf Month	1.66%
Income	-725.88M	PEG	-	EPS next Q	-2.54	Inst Own	108.37%	Short Float / Ratio	9.52% / 2.71	Perf Quarter	51.21%
Sales	38.19M	P/S	104.85	EPS this Y	14.07%	Inst Trans	1.02%	Short Interest	6.09M	Perf Half Y	49.19%
Book/sh	13.50	P/B	4.23	EPS next Y	15.21%	ROA	-59.67%	Target Price	61.17	Perf Year	-37.54%
Cash/sh	13.92	P/C	4.10	EPS next 5Y	-	ROE	-69.95%	52W Range	27.30 - 96.58	Perf YTD	25.98%
Dividend	-	P/FCF	-	EPS past 5Y	-36.50%	ROI	-73.42%	52W High	-40.90%	Beta	0.69
Dividend %	-	Quick Ratio	7.40	Sales past 5Y	116.57%	Gross Margin	78.90%	52W Low	109.08%	ATR	0.65
Employees	593	Current Ratio	7.54	Sales Q/Q	201.97%	Oper. Margin	-2002.75%	RSI (14)	65.60	Volatility	0.74% 0.76%
Optionable	Yes	Debt/Eq	0.05	EPS Q/Q	19.31%	Profit Margin	-1900.65%	Rel Volume	0.44	Prev Close	56.75
Shortable	Yes	LT Debt/Eq	0.04	Earnings	Nov 06 BMO	Payout	-	Avg Volume	2.24M	Price	57.08
Recom	2.80	SMA20	1.22%	SMA50	6.65%	SMA200	33.65%	Volume	995,515	Change	0.58%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-10-23	Upgrade	Citigroup	Neutral → Buy	$51 → $48
Aug-09-23	Upgrade	B. Riley Securities	Neutral → Buy	$45
Aug-09-23	Resumed	Piper Sandler	Overweight	$45
Jul-27-23	Initiated	Scotiabank	Sector Underperform
May-25-23	Upgrade	Oppenheimer	Perform → Outperform
Dec-14-22	Initiated	Needham	Hold
Dec-09-22	Downgrade	Citigroup	Buy → Neutral	$121 → $53
Dec-08-22	Downgrade	JP Morgan	Overweight → Neutral	$94 → $65
Dec-08-22	Downgrade	BMO Capital Markets	Outperform → Market Perform	$110 → $59
Oct-28-22	Initiated	B. Riley Securities	Neutral	$72
Sep-15-22	Initiated	Piper Sandler	Overweight	$110
Jun-07-22	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform	$72
May-20-22	Upgrade	Guggenheim	Neutral → Buy	$115
Feb-01-22	Upgrade	BofA Securities	Underperform → Neutral	$171 → $141
Nov-19-21	Initiated	BMO Capital Markets	Outperform	$187
Sep-23-21	Initiated	Stifel	Buy	$202
Aug-26-21	Initiated	Morgan Stanley	Equal-Weight	$160
Jun-04-21	Upgrade	Citigroup	Neutral → Buy
May-17-21	Downgrade	Oppenheimer	Outperform → Perform
May-10-21	Upgrade	Jefferies	Hold → Buy	$208 → $196

Show Previous Ratings

Nov-29-23 10:45AM	Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment (PR Newswire)
Nov-15-23 01:41PM	Moore Kuehn Encourages PCTI, MRTX, CSTR, and BBAI Investors to Contact Law Firm (PR Newswire)
Nov-10-23 09:00AM	UPDATE 1-Mirati's lung cancer drug gets EU's regulatory backing (Reuters)
07:41AM	EU regulators back Mirati's lung cancer drug (Reuters)
07:30AM	Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure (PR Newswire)
07:44AM	Loading…
Nov-07-23 07:44AM	Mirati's (MRTX) Q3 Loss Narrows, Sales Miss Expectations (Zacks)
01:34AM	Paramount slashed 2 notches to sell; Ameresco in free fall: 5 big analyst cuts (Investing.com)
Nov-06-23 09:02AM	Mirati Therapeutics Inc (MRTX) Reports Q3 2023 Financial Results (GuruFocus.com)
08:00AM	Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates (PR Newswire)
07:28AM	Mirati: Q3 Earnings Snapshot (Associated Press Finance)
Nov-03-23 05:19PM	Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation (PR Newswire)
Nov-02-23 07:30AM	Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRAS -Mutated NSCLC (GlobeNewswire)
Oct-26-23 12:29PM	Moore Kuehn Encourages PNT, VERY, MRTX, and ORTX Investors to Contact Law Firm (PR Newswire)
Oct-19-23 04:11PM	7 Healthcare Stocks That Can Cure a Lackluster Portfolio (InvestorPlace)
Oct-17-23 06:03PM	Moore Kuehn Encourages SP, ORTX, MRTX, and SRT Investors to Contact Law Firm (GlobeNewswire)
04:00PM	Loading…
04:00PM	Mirati Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer (NSCLC) (PR Newswire)
Oct-13-23 07:00AM	Is Bristol Myers Squibb Stock a Buy Now? (Motley Fool)
Oct-12-23 08:24AM	Biotech Stock Roundup: BMY Grabs MRTX, AKRO Down on Study Data, ALNY Faces Setback (Zacks)
Oct-11-23 07:56AM	The Zacks Analyst Blog Highlights Bristol Myers Squibb, Mirati Therapeutics, Eli Lilly, POINT Biopharma and Pfizer (Zacks)
Oct-10-23 11:37AM	Cancer Biotechs Pique Buyout Interest: Recent Deals in Focus (Zacks)
11:28AM	Tango Therapeutics (TNGX) Rises 20% in a Month: Here's Why (Zacks)
07:44AM	Health Care Roundup: Market Talk (The Wall Street Journal)
Oct-09-23 06:12PM	Mirati Therapeutics Snags $5.8 Billion Takeover Deal, But Shares Fall On Lowball Price (Investor's Business Daily) -5.28%
04:14PM	These Stocks Are Moving the Most Today: Exxon, Lockheed, Northrop, Delta, Mirati, Alnylam, SolarEdge, and More (Barrons.com)
02:11PM	Stocks Dig Out Of The Hole In Wake Of Attacks On Israel; Travel Stocks Get Hit (Investor's Business Daily)
02:01PM	Stocks Improve From Larger Losses Prompted By Attacks On Israel; Travel Stocks Get Hit (Investor's Business Daily)
12:06PM	Stock Market Holds Losses Prompted By Attacks On Israel; Oil Stocks Rise With Crude (Investor's Business Daily)
11:58AM	Bristol Myers to buy cancer specialist Mirati for up to $5.8 billion (TheStreet.com)
11:57AM	Bristol-Myers Squibb Buys Mirati Therapeutics to Boost Cancer Drug Portfolio (Investopedia)
11:53AM	Why Shares of Tango Therapeutics Are Dropping Monday (Motley Fool)
11:23AM	Loading…
11:23AM	Bristol Myers Squibb to buy cancer drugmaker Mirati Therapeutics in up to $5.8B deal (Fox Business)
10:54AM	Stock Market Sinks After Attacks On Israel; Defense Stocks Benefit (Investor's Business Daily)
10:24AM	Bristol Myers (BMY) to Acquire Mirati Therapeutics for $5.8 B (Zacks)
10:08AM	Bristol-Myers Squibb to acquire Mirati in deal worth up to $5.8B (Yahoo Finance Video)
10:01AM	Mirati (MRTX) Gets Buyout Offer From Bristol Myers for $4.8B (Zacks)
09:51AM	Bristol Myers to Buy Mirati. Why Mirati Stock Is Falling. (Barrons.com)
09:33AM	Oracle upgraded, Spotify downgraded: Wall Street's top analyst calls (The Fly)
08:36AM	Mirati Stock Falls as Bristol Myers to Buy Oncology Developer for Up to $5.8 Billion (Barrons.com)
07:59AM	5 Things to Know Before Markets Open (Investopedia)
03:26AM	Bristol-Myers Squibb shells out billions for Mirati: 5 big deal reports (Investing.com)
Oct-08-23 06:12PM	Bristol Myers Squibb to Acquire Mirati Therapeutics in Deal Worth Up to $5.8 Billion (The Wall Street Journal)
05:55PM	Bristol-Myers Squibb to acquire Mirati in up to $5.8 billion deal (Reuters)
05:54PM	UPDATE 4-Bristol-Myers Squibb to acquire Mirati in up to $5.8 billion deal (Reuters)
05:30PM	Bristol-Myers Squibb to acquire Mirati Therapeutics for $58 per share (Reuters)
05:16PM	Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics (Business Wire)
Oct-06-23 11:34AM	Mirati (MRTX) Surges 45% as Sanofi Reportedly Eyes Buyout (Zacks)
05:08AM	Sanofi Is Exploring Acquisition of Cancer Drugmaker Mirati (Bloomberg)
Oct-05-23 03:16PM	Sanofi to explore acquisition of cancer drugmaker Mirati- Bloomberg News (Reuters) +45.44%
03:08PM	UPDATE 2-Sanofi to explore acquisition of cancer drugmaker Mirati- Bloomberg News (Reuters)
Sep-27-23 04:30PM	Mirati To Present Updated Clinical Data at ESMO Congress 2023 (PR Newswire)
Sep-09-23 10:35PM	Mirati Presents Two-Year Follow-Up Data from KRYSTAL-1 Study Demonstrating Durable Response and Long-Term Overall Survival at 2023 World Conference on Lung Cancer (PR Newswire)
Sep-05-23 04:01PM	Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire) -5.25%
Aug-29-23 04:00PM	Mirati Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference (PR Newswire)
Aug-23-23 04:00PM	Mirati Therapeutics Announces Departure of Chief Financial Officer Laurie Stelzer (PR Newswire)
Aug-21-23 04:00PM	Mirati To Present Pooled Clinical Data from Adagrasib's KRYSTAL-1 Study Demonstrating Overall Survival Results at Two-Years of Follow-Up at 2023 World Conference on Lung Cancer (PR Newswire)
Aug-19-23 07:40AM	3 Under-the-Radar Biotech Stocks to Buy in 2023 (Motley Fool)
Aug-16-23 11:02AM	BOXER CAPITAL, LLC Boosts Stake in Mirati Therapeutics Inc (GuruFocus.com)
Aug-11-23 04:00PM	Mirati Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Aug-10-23 10:12AM	Penn downgraded, Roblox upgraded: Wall Street's top analyst calls (The Fly) +5.95%
Aug-09-23 04:01PM	Mirati Rockets 33% On A Bevy Of News In Cancer, A $300 Million Deal And Its CEO Exit (Investor's Business Daily) +33.09%
04:00PM	Cancer Discovery Publishes Preclinical and Initial Clinical Data for MRTX1719 to Treat MTAP-Deleted Cancers through Novel Approach to MTA-Cooperative PRMT5 Inhibition (PR Newswire)
10:56AM	Why Shares of Mirati Therapeutics Are Jumping Wednesday (Motley Fool)
10:26AM	UPS downgraded, Eli Lilly upgraded: Wall Street's top analyst calls (The Fly)
09:42AM	Mirati (MRTX) Q2 Earnings Beat, Stock Up on Solid Krazati Sales (Zacks)
08:37AM	Q2 2023 Mirati Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
12:31AM	Mirati Therapeutics Announces Pricing of Upsized Public Offering (PR Newswire)
Aug-08-23 04:58PM	Mirati: Q2 Earnings Snapshot (AP Finance)
04:02PM	Mirati Therapeutics Announces Proposed Public Offering (PR Newswire)
04:01PM	Mirati Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Updates (PR Newswire)
04:00PM	Mirati Therapeutics Announces Departure of Chief Executive Officer David Meek (PR Newswire)
Aug-03-23 04:01PM	Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Jul-28-23 02:00AM	Superyacht Dinners and Alleged Insider Tips Ensnare Billionaire (Bloomberg)
Jul-26-23 02:46PM	RPT-UPDATE 6-British billionaire Joe Lewis pleads not guilty to US insider trading charges (Reuters)
02:09PM	UPDATE 6-British billionaire Joe Lewis pleads not guilty to US insider trading charges (Reuters)
Jul-25-23 04:30PM	Mirati Therapeutics® to Report Second Quarter 2023 Financial Results and Recent Corporate Updates on August 8, 2023 (PR Newswire)
Jul-21-23 07:56AM	Mirati Therapeutics Provides Update on Regulatory Review in the European Union of KRAZATI (adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRAS G12C Mutation (PR Newswire) -7.39%
06:19AM	EU regulator declines to back Mirati's lung cancer drug (Reuters)
Jul-03-23 09:00AM	Top Growth Stocks for July 2023 (Investopedia) +5.37%
Jul-01-23 09:00AM	Top Stocks for July 2023 (Investopedia)
Jun-28-23 08:29AM	Will Mirati Therapeutics (NASDAQ:MRTX) Spend Its Cash Wisely? (Simply Wall St.)
Jun-23-23 04:00PM	Mirati Therapeutics Appoints Industry Veteran Carol Gallagher, Pharm.D. as New Independent Director (PR Newswire)
Jun-20-23 08:00AM	Journal of Clinical Oncology Publishes Clinical Results of Adagrasib as a Targeted Treatment for KRASG12C-Mutated NSCLC with Untreated Central Nervous System (CNS) Metastases (PR Newswire)
Jun-01-23 04:30PM	Mirati Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023 (PR Newswire)
11:35AM	Biotech Stock Roundup: MRTX Falls on Study Failure, LXRX Drug Wins Approval & More (Zacks)
10:23AM	Top Stocks for June 2023 (Investopedia)
May-30-23 08:45PM	Oppenheimer Sees Over 50% Gains in These 2 Stocks Heres Why They Could Soar (TipRanks)
04:00PM	Mirati To Encore Compelling Clinical Data Demonstrating Adagrasib's Potential as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors at 2023 ASCO Annual Meeting (PR Newswire)
May-25-23 10:15AM	Mirati's Sitravatinib Flunks Phase 3 Combo Therapy Study In Type Of Lung Cancer Setting (Benzinga) -12.41%
May-24-23 04:01PM	Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO® (PR Newswire)
May-14-23 08:14AM	Growth Investors: Industry Analysts Just Upgraded Their Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenue Forecasts By 23% (Simply Wall St.)
May-11-23 06:11AM	Mirati Therapeutics First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
May-10-23 11:53AM	Mirati (MRTX) Q1 Earnings & Revenues Beat Estimates, Stock Up (Zacks)
May-09-23 04:27PM	Mirati: Q1 Earnings Snapshot (AP Finance)
04:01PM	Mirati Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Updates (PR Newswire)
May-08-23 08:30AM	Mirati Therapeutics and Sarah Cannon Research Institute Announce Strategic, Community Site Focused Partnership to Increase Diversity in Oncology Clinical Studies (PR Newswire)
May-05-23 04:00PM	Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Apr-27-23 04:30PM	Mirati Therapeutics to Participate at the Bank of America Securities 2023 Health Care Conference (PR Newswire)
Apr-26-23 04:33PM	Journal of Clinical Oncology Publishes Rapid Communication Featuring Updated Clinical Data for Adagrasib as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors (PR Newswire)
Apr-25-23 04:30PM	Mirati Therapeutics® to Report First Quarter 2023 Financial Results and Recent Corporate Updates on May 9, 2023 (PR Newswire)
Apr-15-23 09:11AM	Mirati Therapeutics (NASDAQ:MRTX) shareholders have endured a 57% loss from investing in the stock three years ago (Simply Wall St.)

Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Christensen Jamie	EVP & Chief Scientific Officer	Sep 08	Sale	35.63	2,388	85,084	144,032	Sep 12 05:41 PM
Boxer Capital, LLC		Aug 11	Buy	27.80	1,201,440	33,400,032	3,201,440	Aug 15 09:39 PM
Boxer Capital, LLC		Aug 11	Buy	27.80	1,201,440	33,400,032	3,201,440	Aug 15 09:38 PM
Boxer Capital, LLC		Aug 11	Buy	27.80	57,533	1,599,417	287,866	Aug 15 09:39 PM
Boxer Capital, LLC		Aug 11	Buy	27.80	57,533	1,599,417	287,866	Aug 15 09:38 PM
Hasnain Faheem	Director	Aug 11	Buy	27.80	10,791	299,990	10,791	Aug 14 04:41 PM
Stelzer Laurie	Chief Financial Officer	Jun 02	Sale	37.06	4,647	172,218	80,015	Jun 02 07:15 PM
Christensen Jamie	EVP & Chief Scientific Officer	May 24	Sale	45.29	619	28,035	124,123	May 24 07:38 PM
Cherrington Julie M	Director	Jan 18	Sale	44.66	2,546	113,704	0	Jan 20 09:20 AM
Meek David D.	Chief Executive Officer	Jan 17	Sale	42.38	3,179	134,715	61,792	Jan 19 09:45 AM
Christensen Jamie	EVP, Chief Scientific Officer	Jan 17	Sale	42.38	2,245	95,142	97,878	Jan 19 09:45 AM
Hickey Benjamin	EVP, Chief Commercial Officer	Jan 17	Sale	42.38	1,566	66,366	47,223	Jan 19 09:45 AM
Hickey Benjamin	EVP, Chief Commercial Officer	Jan 09	Sale	45.37	2,088	94,733	48,789	Jan 10 05:00 PM
BAUM CHARLES M	President,Founder,Head of R&D	Jan 04	Sale	46.60	3,648	169,997	168,777	Jan 05 05:13 PM
Christensen Jamie	EVP, Chief Scientific Officer	Jan 04	Sale	46.60	1,949	90,823	100,123	Jan 05 05:13 PM
BAUM CHARLES M	President,Founder,Head of R&D	Dec 21	Sale	40.42	9,092	367,469	172,425	Dec 21 09:21 PM
Meek David D.	Chief Executive Officer	Dec 21	Sale	40.41	4,616	186,552	64,971	Dec 21 09:20 PM
Hickey Benjamin	EVP, Chief Commercial Officer	Dec 21	Sale	40.41	3,248	131,266	50,877	Dec 21 09:20 PM
Christensen Jamie	EVP, Chief Scientific Officer	Dec 16	Sale	43.00	2,410	103,624	102,072	Dec 20 04:02 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MRTX

Mirati Therapeutics Inc

Upgrade your FINVIZ experience